Clinical efficacy of telbivudine in the treatment of chronic hepatitis B with poor response to adefovir dipivoxil for 24 months
TAN Shu-yan
ZOU Min-chao
SHANGGUAN Hui
Abstract：Objective To evaluate the clinical effecacy of telbivudine in the treatment of chronic hepatitis B patients with poor response to adefovir dipivoxil for 24 months. Methods 66 cases of HBeAg-positive chronic hepatitis B patients with poor response to adefovir dipivoxil were randomly divided into two groups. Group A was given telbivudine (600mg·d-1). Group B was given telbivudine and adefovir dipivoxil (10mg?d-1). The differences of ALT normaIization rate, HBeAg/HBeAb seroconversion rate and HBV-DNA negative rate between the two groups were compared after 24-month therapy. Results After 24-month therapy, HBV-DNA negative rate and HBeAg/HBeAb seroconversion rate for group A were 78.8%and 21.2%, while those for group B were 97.0%and 45.5%. The indicators of group B were significantIy better than group A. Four cases (12.1%) of group A but none of group B appeared viral resistance. No patient terminated the treatment due to severe adverse event. Conclusion Combination of telbivudine and adefovir dipivoxil has good effect for patients of HBeAg-positive chronic hepatitis B with poor response to adefovir dipivoxil. The treatment is safe and of low viral resistance rate.
Keywords：hepatitis BchronicTherapytelbivudineadefovir dipivoxil
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 31-33 )